Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 100
- Registration Number
- NCT04367311
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 30
- Registration Number
- NCT03713944
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 6
- Registration Number
- NCT02679950
- Locations
- 🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 14
- Registration Number
- NCT02429466
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Indiana University Hospital, Indianapolis, Indiana, United States